Navigation Links
Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
Date:12/28/2009

BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading provider of biopharmaceutical products in China, announced today that Weidong Yin, Chairman, President & CEO, was presented with the Annual Innovation Award by China Central Television (CCTV). As previously announced, Mr. Yin had been one of 18 nominees for the CCTV's China's 2009 Economic Man-of-the-Year. Results were announced on December 23, 2009 at an award ceremony held in Beijing.

Mr. Weidong Yin was honored because of his contribution to the battle against the H1N1 influenza pandemic; Sinovac vaccines protect human life and strengthen the Chinese people's confidence.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "I am very pleased to have received CCTV's 2009 Annual Innovation Award. As the first company worldwide to receive approval for the H1N1 vaccine, we have exemplified Sinovac's position as a true innovator in the global vaccine industry. We are proud that our entire portfolio of innovative vaccines continues to make a significant contribution to the health and well-being of Chinese citizens."

Recipients of the Top Ten 2009 Economic Man-of-the-Year award were CEO and president of Sina Charles Chao, China Minsheng Banking Corporation Chairman Dong Wenbiao, Shenzhen Capital Group Chairman Jin Haitao, chairman of Geely Automobile Holding Li Shufu, Guangdong Galanz Enterprise Group CEO Liang Chao-Hsien, chairman of Jiangsu Shagang Group Shen Wenrong, chairman and CEO at Neusoft Group Ltd Liu Jiren, Phoenix Publishing & Media Group chairman Tan Yue, Chongqing Changan Automobile Co., Ltd., chairman Xu Liuping, and chairman of New Oriental Education Group Yu Minhong. In addition, Liu Haitao, head of Shanghai Institute of Microsystem and Information Technology under the Chinese Academy of Sciences, received the Annual Innovation Award.

About Sinov
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
5. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
6. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
7. Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009
8. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
9. Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
10. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
11. $10,000 ISSAC Award for Innovation Presented to MIT PhD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... (OTCQB: ILIU) today issued financial and operational results for ... December 31, 2010. "We made good ... with Stanford University, data from a clinical study was ... genetics has in improving weight loss.  Our Inherent Health ...
... FRANCISCO, March 21, 2011 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) agonists and antagonists ... diseases, announced today the presentation of positive clinical ... VTX-1463 for the treatment of allergic rhinitis. The ...
... SAN CARLOS, Calif., March 21, 2011 WaferGen ... ), a leading developer of state-of-the-art genomic analysis ... innovative genomic samples preparation, today announced they will ... gene expression profiling and target enrichment to enable ...
Cached Biology Technology:Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 2Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 3Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 4Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 5Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 6Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results 7VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4
(Date:5/22/2013)... 2013 U.S. Forest Service scientists are part of ... from the TKF Foundation, will examine how collaborative planning ... recover from tragedy. , The TKF Foundation announced today ... selected for grant funding. In addition to research on ... recovery and resiliency, the 3-year, $585,000 grant will contribute ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... genetic engineering drastically reduces the time and effort ... workhorses of biotechnology, scientists are reporting. Published in ... method paves the way for more rapid development ... and other activities. , Keith Shearwin and colleagues ... the genetic material DNA into a bacterium,s genome ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... Biochemist Glenn King is searching for an alternative to ... one the world's most efficient insect predators -- spiders. ... large Australian spider with a bite that is deadly ... of venom for King's research. The spider "cooperates" by ...
... B cell chronic lymphocytic leukemia (B-CLL),is the most ... the,progressive accumulation of mature B lymphocytes in the ... that in the early stages,of disease, B-CLL is ... signals that trigger normal B cell death (apoptosis). ...
... rapid advancement of biomedical science and the development ... types of information from biomedical text has become ... quite useful for interpreting large amounts of high-throughput ... information related to gene functions from text has ...
Cached Biology News:Spider Venom Could Yield Eco-Friendly Insecticides 2Spider Venom Could Yield Eco-Friendly Insecticides 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Biology Products: